menu
    • menu

    Find Retatrutide manufacturers, exporters & distributors on PharmaCompass

    Retatrutide

    Virtual Booth

    Contact Supplier

    Kikkoman Biochemifa Company advances global health and safety through precision-driven innovation in biotech and food testing.

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    Retatrutide

    Virtual Booth

    Contact Supplier

    Moehs Group, a reference company in the production of pharmaceutical active ingredients.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-10-20

    Virtual Booth

    Contact Supplier

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass

    Synopsis

    Product SearchProduct Search

    Synopsis

    ACTIVE PHARMA INGREDIENTS

    26

    API Suppliers

    API Suppliers

    1

    USDMF

    US DMFs Filed

    0

    CEP/COS

    CEP/COS Certifications

    0

    JDMF

    JDMFs Filed

    0

    EU WC

    EU WC

    0

    KDMF

    KDMF

    17

    NDC API

    NDC API

    0

    VMF

    NDC API

    10

    Listed Suppliers

    Other Suppliers

    0INTERMEDIATES

    REF. STANDARDS OR IMPURITIES

    0

    EDQM

    0

    USP

    0

    JP

    0

    Others

    FINISHED DOSAGE FORMULATIONS

    0

    FDF Dossiers

    FDF Dossiers

    0

    FDA Orange Book

    FDA (Orange Book)

    0

    Europe

    Europe

    0

    Canada

    Canada

    0

    Australia

    Australia

    0

    South Africa

    South Africa

    0

    Listed Dossiers

    Listed Dossiers

    40DRUGS IN DEVELOPMENT

    FDF Dossiers

    DRUG PRODUCT COMPOSITIONS

    0RELATED EXCIPIENT COMPANIES

    0EXCIPIENTS BY APPLICATIONS

    PATENTS & EXCLUSIVITIES

    0

    US Patents

    0

    US Exclusivities

    0

    Health Canada Patents

    API REF. PRICE (USD/KG)

    $
    $ 0

    GLOBAL SALES INFORMATION

    US Medicaid

    NA

    Annual Reports

    NA

    Regulatory FDF Prices

    NA

    API/FDF Prices: Book a Demo to
    explore the features and consider
    upgrading later

    MARKET PLACE

    1

    API

    0

    FDF

    DIGITAL CONTENT

    1

    Data Compilation #PharmaFlow

    0

    Stock Recap #PipelineProspector

    0

    Weekly News Recap #Phispers

    2

    News #PharmaBuzz

    Chemistry

    Click the arrow to open the dropdown
    read-moreClick the button for full data set
    read-moreClick the button for full data set
    Also known as: Retatrutide api
    Retatrutide (LY3437943) is a biologic entity that acts as a triagonist for the gastric inhibitory polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor. It is an investigational drug developed by Eli Lilly for obesity, type 2 diabetes, and related metabolic disorders.

    API SUPPLIERS

    read-more
    read-more

    01

    Fujian Genohope Biotech

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI WW Frankfurt
    Booth #3.0A88
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothFujian Genohope Biotech is a leading provider of high-potency peptide APIs, offering GMP quality and worldwide delivery.

    Contact Supplier Contact Supplier
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 84502-105

    Start Marketing Date : 2025-03-07

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1g/g)

    Marketing Category : BULK INGREDIENT

     KDMF VMF Others AUDIT
    Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Shanghai Minbiotech

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI WW Frankfurt
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothShanghai Minbiotech is the leading producer of biopharmaceuticals and a variety of high-end generic & innovative drugs.

    Contact Supplier Contact Supplier
    Flag China
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Shanghai Minbiotech CB

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Cayman Chemical Company Inc

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    OTS 2025
    Not Confirmed
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Cayman

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Omgene Life Sciences Pvt. Ltd

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI WW Frankfurt
    Booth #12.1F127
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothOmgene: R&D-based biopharmaceutical company with GMP facilities, focused on innovation and high-quality, affordable medicines.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Omgene Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Vtides Life Sciences Pvt. Ltd

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    CPhI WW Frankfurt
    Attending
    • fda
    • EDQM
    • WHO-GMP

    Virtual BoothVtides Life Sciences: Pioneering Peptide API Development & Manufacturing in State-of-the-art GMP Facilities Since 2024.

    Contact Supplier Contact Supplier
    Flag India
    Virtual Booth Virtual Booth
    Digital Content Digital Content
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    Company Banner

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Protheragen

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    OTS 2025
    Not Confirmed
    arrow

    Protheragen

    U.S.A

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    OTS 2025
    Not Confirmed
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Hangzhou Taijia Biotechnology

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    OTS 2025
    Not Confirmed
    arrow

    08

    Tian Yuan Pharm

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    OTS 2025
    Not Confirmed
    arrow

    Tian Yuan Pharm

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    OTS 2025
    Not Confirmed
    USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Xiushi Biopharma

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    OTS 2025
    Not Confirmed
    arrow

    Xiushi Biopharma

    China

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    OTS 2025
    Not Confirmed
    USDMF CEP/COS JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 84689-400

    Start Marketing Date : 2025-04-27

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1g/g)

    Marketing Category : BULK INGREDIENT

     KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Country

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    OTS 2025
    Not Confirmed
    arrow

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    OTS 2025
    Not Confirmed
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 41577

    Submission : 2025-03-19

    Status : Active

    Type : II

     CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    USDMF

    read-more
    read-moreread-more

    01

    Sichuan Jisheng Biopharmaceutical Co...

    Country

    USDMF

    arrow
    ISPE Annual Meeting
    Not Confirmed

    01

    Sichuan Jisheng Biopharmaceutical Co...

    Country
    arrow
    ISPE Annual Meeting
    Not Confirmed

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 41577

    Submission : 2025-03-19

    Status : Active

    Type : II

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

    Details:

    Tirzepatide is a Peptide, Unconjugated drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.


    Lead Product(s): Tirzepatide,Retatrutide

    Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Peptide, Unconjugated

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable September 10, 2025

    blank

    01

    Eli Lilly

    U.S.A
    arrow
    Aus. Peptide Conference
    Not Confirmed

    Eli Lilly

    U.S.A
    arrow
    Aus. Peptide Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Tirzepatide,Retatrutide

    Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liv...

    Details : Tirzepatide is a Peptide, Unconjugated drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Non-alcoholic Fatty Liver Disease.

    Product Name : Undisclosed

    Product Type : Peptide, Unconjugated

    Upfront Cash : Inapplicable

    September 10, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Study of Retatrutide LY3437943 in Obesity or Overweight Patient with Chronic Low Back Pain

    Details:

    Retatrutide is a Peptide drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Obesity.


    Lead Product(s): Retatrutide,Inapplicable

    Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Peptide, Unconjugated

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable June 24, 2025

    blank

    02

    Eli Lilly

    U.S.A
    arrow
    Aus. Peptide Conference
    Not Confirmed

    Eli Lilly

    U.S.A
    arrow
    Aus. Peptide Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Retatrutide,Inapplicable

    Therapeutic Area : Nutrition and Weight Loss

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Study of Retatrutide LY3437943 in Obesity or Overweight Patient with Chronic Low Back Pain

    Details : Retatrutide is a Peptide drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Obesity.

    Product Name : Undisclosed

    Product Type : Peptide, Unconjugated

    Upfront Cash : Inapplicable

    June 24, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Retatrutide Effect On Insulin Secretion and Sensitivity In T2DM Adults

    Details:

    Retatrutide is a Peptide drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Diabetes Mellitus.


    Lead Product(s): Retatrutide,Inapplicable

    Therapeutic Area: Endocrinology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Peptide, Unconjugated

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable May 21, 2025

    blank

    03

    Eli Lilly

    U.S.A
    arrow
    Aus. Peptide Conference
    Not Confirmed

    Eli Lilly

    U.S.A
    arrow
    Aus. Peptide Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Retatrutide,Inapplicable

    Therapeutic Area : Endocrinology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Retatrutide Effect On Insulin Secretion and Sensitivity In T2DM Adults

    Details : Retatrutide is a Peptide drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Diabetes Mellitus.

    Product Name : Undisclosed

    Product Type : Peptide, Unconjugated

    Upfront Cash : Inapplicable

    May 21, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Retatrutide Response to Hypoglycemia In Type 2 Diabetes

    Details:

    Retatrutide is a Peptide drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Diabetes Mellitus, Type 2.


    Lead Product(s): Retatrutide,Inapplicable

    Therapeutic Area: Endocrinology Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Peptide, Unconjugated

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable May 21, 2025

    blank

    04

    Eli Lilly

    U.S.A
    arrow
    Aus. Peptide Conference
    Not Confirmed

    Eli Lilly

    U.S.A
    arrow
    Aus. Peptide Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Retatrutide,Inapplicable

    Therapeutic Area : Endocrinology

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Retatrutide Response to Hypoglycemia In Type 2 Diabetes

    Details : Retatrutide is a Peptide drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Diabetes Mellitus, Type 2.

    Product Name : Undisclosed

    Product Type : Peptide, Unconjugated

    Upfront Cash : Inapplicable

    May 21, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity

    Details:

    Retatrutide is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Obesity.


    Lead Product(s): Retatrutide,Inapplicable

    Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Peptide, Unconjugated

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable March 05, 2025

    blank

    05

    Eli Lilly

    U.S.A
    arrow
    Aus. Peptide Conference
    Not Confirmed

    Eli Lilly

    U.S.A
    arrow
    Aus. Peptide Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Retatrutide,Inapplicable

    Therapeutic Area : Nutrition and Weight Loss

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obes...

    Details : Retatrutide is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Obesity.

    Product Name : Undisclosed

    Product Type : Peptide, Unconjugated

    Upfront Cash : Inapplicable

    March 05, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants

    Details:

    Retatrutide is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.


    Lead Product(s): Retatrutide,Metoprolol Tartrate

    Therapeutic Area: Undisclosed Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Peptide, Unconjugated

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable February 05, 2025

    blank

    06

    Eli Lilly

    U.S.A
    arrow
    Aus. Peptide Conference
    Not Confirmed

    Eli Lilly

    U.S.A
    arrow
    Aus. Peptide Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Retatrutide,Metoprolol Tartrate

    Therapeutic Area : Undisclosed

    Highest Development Status : Phase I

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Par...

    Details : Retatrutide is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.

    Product Name : Undisclosed

    Product Type : Peptide, Unconjugated

    Upfront Cash : Inapplicable

    February 05, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    CDSCO Panel Approves Eli Lilly's Protocol Amendment Proposal for Retatrutide Study

    Details:

    LY3437943 (retatrutide) is a GCGR/GLP-1R agonist synthetic peptide candidate, which is currently being evaluated for the treatment of Atherosclerotic Cardiovascular Disease in adult.


    Lead Product(s): Retatrutide,Inapplicable

    Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Peptide, Unconjugated

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable January 19, 2025

    blank

    07

    Eli Lilly

    U.S.A
    arrow
    Aus. Peptide Conference
    Not Confirmed

    Eli Lilly

    U.S.A
    arrow
    Aus. Peptide Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Retatrutide,Inapplicable

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    CDSCO Panel Approves Eli Lilly's Protocol Amendment Proposal for Retatrutide Study

    Details : LY3437943 (retatrutide) is a GCGR/GLP-1R agonist synthetic peptide candidate, which is currently being evaluated for the treatment of Atherosclerotic Cardiovascular Disease in adult.

    Product Name : Undisclosed

    Product Type : Peptide, Unconjugated

    Upfront Cash : Inapplicable

    January 19, 2025

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

    Details:

    Retatrutide is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Obesity.


    Lead Product(s): Retatrutide,Inapplicable

    Therapeutic Area: Nutrition and Weight Loss Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Peptide, Unconjugated

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable October 28, 2024

    blank

    08

    Eli Lilly

    U.S.A
    arrow
    Aus. Peptide Conference
    Not Confirmed

    Eli Lilly

    U.S.A
    arrow
    Aus. Peptide Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Retatrutide,Inapplicable

    Therapeutic Area : Nutrition and Weight Loss

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

    Details : Retatrutide is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Obesity.

    Product Name : Undisclosed

    Product Type : Peptide, Unconjugated

    Upfront Cash : Inapplicable

    October 28, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

    Details:

    Retatrutide is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Atherosclerosis.


    Lead Product(s): Retatrutide,Inapplicable

    Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Peptide, Unconjugated

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable April 25, 2024

    blank

    09

    Eli Lilly

    U.S.A
    arrow
    Aus. Peptide Conference
    Not Confirmed

    Eli Lilly

    U.S.A
    arrow
    Aus. Peptide Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Retatrutide,Inapplicable

    Therapeutic Area : Cardiology/Vascular Diseases

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Liv...

    Details : Retatrutide is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Atherosclerosis.

    Product Name : Undisclosed

    Product Type : Peptide, Unconjugated

    Upfront Cash : Inapplicable

    April 25, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRA...

    Details:

    Retatrutide is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetes Mellitus, Type 2.


    Lead Product(s): Retatrutide,Inapplicable

    Therapeutic Area: Endocrinology Brand Name: Undisclosed

    Study Phase: Phase IIIProduct Type: Peptide, Unconjugated

    Sponsor: Undisclosed

    Deal Size: Inapplicable Upfront Cash: Inapplicable

    Deal Type: Inapplicable April 09, 2024

    blank

    10

    Eli Lilly

    U.S.A
    arrow
    Aus. Peptide Conference
    Not Confirmed

    Eli Lilly

    U.S.A
    arrow
    Aus. Peptide Conference
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Retatrutide,Inapplicable

    Therapeutic Area : Endocrinology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Undisclosed

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequ...

    Details : Retatrutide is a Peptide drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Diabetes Mellitus, Type 2.

    Product Name : Undisclosed

    Product Type : Peptide, Unconjugated

    Upfront Cash : Inapplicable

    April 09, 2024

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    DATA COMPILATION #PharmaFlow

    read-more
    read-more

    NEWS #PharmaBuzz

    read-more
    read-more
    Umbrella Labs Launches Retatrutide for Scientific Research
    Umbrella Labs Launches Retatrutide for Scientific Research

    20 Jun 2025

    // ACCESSWIRE

    https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/umbrella-labs-launches-retatrutide-ly3437943-for-scientific-research-1039260

    ACCESSWIRE
    20 Jun 2025
    Share Share
    Umbrella Labs Adds Retatrutide (LY3437943) to Research Portfolio
    Umbrella Labs Adds Retatrutide (LY3437943) to Research Portfolio

    02 Jun 2025

    // ACCESSWIRE

    https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/umbrella-labs-expands-research-portfolio-with-availability-of-retatru-1033723

    ACCESSWIRE
    02 Jun 2025
    Share Share

    Market Place

    Do you need sourcing support? Ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search